Correspondence 0001493152-23-013508 from ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc.
Date: April 25, 2023 · CIK: 0001859007 · Accession: 0001493152-23-013508
AI Filing Summary & Sentiment
Show Raw Text
CORRESP
1
filename1.htm
A.G.P./ALLIANCE
GLOBAL PARTNERS
590
Madison Avenue 28th Floor New York,
New
York 10022
April
25, 2023
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re:
ZyVersa Therapeutics, Inc. (the “Company”)
Registration
Statement on Form S-1
File
No. 333- 269442 (the “Registration Statement”)
Ladies
and Gentlemen:
Reference
is made to our letter filed as correspondence via EDGAR on April 21, 2023, in which we, as the lead placement agent, requested the acceleration
of the effective date of the above-captioned Registration Statement for April 24, 2023 at 5:00 p.m. Eastern Time, in accordance with
Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended.
We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request
for acceleration of the effective date.
Very
truly yours,
A.G.P./ALLIANCE
GLOBAL PARTNERS
By:
/s/
Thomas Higgins
Name:
Thomas
Higgins
Title:
Managing
Director